PUBLISHER: DelveInsight | PRODUCT CODE: 1226567
PUBLISHER: DelveInsight | PRODUCT CODE: 1226567
"MIN-102 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about MIN-102 for Adrenoleukodystrophy in the 7MM. A detailed picture of the MIN-102 for Adrenoleukodystrophy in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the MIN-102 for Adrenoleukodystrophy. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MIN-102 market forecast, analysis for Adrenoleukodystrophy in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Adrenoleukodystrophy.
Leriglitazone (MIN-102) is under development by Minoryx Therapeutics. It is a novel, orally bioavailable, and selective PPAR gamma agonist with a superior profile for CNS-related diseases. It is a metabolite of pioglitazone, which shows an excellent brain penetration and safety profile, allowing PPAR gamma engagement in the CNS above the level that can be safely achieved with pioglitazone and other glitazones. In X-ALD, mutations on ABCD1 trigger a cascade of events leading to mitochondrial dysfunction, oxidative stress, neuroinflammation, demyelination, and axonal degeneration.
MIN-102, through its PPAR gamma activity, prevents such dysfunctions; thus, it has the potential to treat both AMN and CALD. It also reduces monocyte adhesion to the endothelial cells of the blood-brain barrier (BBB). This mechanism leads to BBB disruption and has a prominent role in the initiation of the CALD phenotype. The mechanism of action of leriglitazone in X-ALD was published in the Science Translational Medicine Journal.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
MIN-102 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of MIN-102 in Adrenoleukodystrophy in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of MIN-102 for Adrenoleukodystrophy covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions